Abstract: The present inventors attempted to produce antibodies that neutralize the activity of a substance having an activity of functionally substituting for FVIII to be used for the method of measuring the reactivity of FVIII in the presence of a substance having an activity of functionally substituting for FVIII. As a result, the inventors discovered that by using the produced antibodies, FVIII activity in the plasma of a hemophilia A patient can be evaluated accurately by one-stage clotting assay based on APTT, and also that FVIII inhibitor titer in the plasma of a hemophilia A patient carrying a FVIII inhibitor can be evaluated accurately by Bethesda assay based on APTT.
Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the Fc?RI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the C?2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the C?2 domain of IgE) and/or the ability to disassociate IgE from the Fc?RI receptor for instance at pharmaceutically-relevant concentrations.
Type:
Grant
Filed:
June 8, 2017
Date of Patent:
January 4, 2022
Assignee:
UCB BIOPHARMA SRL
Inventors:
Ralph Adams, Thomas Allen Ceska, Anna Marie Davies, Alistair James Henry, Xiaofeng Liu, James Michael McDonnell, Brian John Sutton, Marta Katarzyna Westwood
Abstract: The present invention provides an anti-LAG-3 antibody capable of repeated administration even to animals other than rat. An anti-LAG-3 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLLDSDGNTY (SEQ ID NO: 16), CDR2 having the amino acid sequence of SVS and CDR3 having the amino acid sequence of MQATHVPFT (SEQ ID NO: 17) and the light chain constant region of an antibody of an animal other than rat; and (b) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GFDFDTYP (SEQ ID NO: 18), CDR2 having the amino acid sequence of ITIKTHNYAT (SEQ ID NO: 19) and CDR3 having the amino acid sequence of NREDFDY (SEQ ID NO: 20) and the heavy chain constant region of an antibody of an animal other than rat. A pharmaceutical composition comprising the above anti-LAG-3 antibody as an active ingredient. A method for preparing the above anti-LAG-3 antibody is also provided.
Type:
Grant
Filed:
August 10, 2017
Date of Patent:
December 14, 2021
Assignees:
Fuso Pharmaceutical Industries, Ltd., National University Corporation Hokkaido University
Abstract: The present invention relates to the use of phosphotidylserine or pathogenic sugar targeted therapeutics for the management and treatment of microbial infections, including Zika, Dengue, West Nile, Ebola, H1N1, enteroviruses, Leishmaniasis, Malaria and Coronaviruses SARS-COV.
Abstract: The present invention provides methods of administering long-acting Factor IX; methods of administering long-acting, chimeric and hybrid polypeptides comprising Factor IX; and methods of producing such chimeric and hybrid polypeptides using cells.
Type:
Grant
Filed:
June 9, 2017
Date of Patent:
December 7, 2021
Assignee:
Bioverativ Therapeutics Inc.
Inventors:
Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang, Mark Brader
Abstract: The present invention provides a chimeric protein comprising a first polypeptide which comprises a FVIII protein and a first Ig constant region or a portion thereof and a second polypeptide which comprises a VWF protein comprising the D? domain and D3 domain of VWF, a XTEN sequence having less than 288 amino acids in length, and a second Ig constant region or a portion thereof, wherein the first polypeptide and the second polypeptide are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins.
Type:
Grant
Filed:
January 9, 2015
Date of Patent:
December 7, 2021
Assignee:
Bioverativ Therapeutics Inc.
Inventors:
Ekta Seth Chhabra, Tongyao Liu, Robert T. Peters, John Kulman
Abstract: The present invention relates to a polypeptide comprising an epitope of an antigen; a kit and a composition for diagnosing allergy, wherein the kit and the composition comprise the aforementioned polypeptide, and a method for diagnosing allergy and a method for treating allergy, wherein the methods use the aforementioned polypeptide; a pharmaceutical composition comprising the aforementioned polypeptide; and a raw material or a processed product in which the antigen comprising the aforementioned polypeptide is removed or reduced. Furthermore, the present invention relates to a tester for determining the presence or absence of the antigen in an object.
Abstract: Disclosed herein are methods of selecting an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer. Also disclosed are methods of selecting a donor from whom to derive an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer.
Type:
Grant
Filed:
November 4, 2015
Date of Patent:
November 16, 2021
Assignee:
Memorial Sloan Kettering Cancer Center
Inventors:
Richard J. O'Reilly, Ekaterina Doubrovina, Guenther Koehne, Aisha N. Hasan, Susan E. Prockop
Abstract: Novel antibodies, such as single domain antibodies (sdAbs), or fragments thereof that specifically bind a transferrin are described. Compositions, methods and systems for increasing the half-life of a target protein in a serum using an antibody or fragment thereof against a transferrin are described.
Type:
Grant
Filed:
July 1, 2019
Date of Patent:
November 9, 2021
Assignee:
Nanjing Legend Biotech Co., Ltd.
Inventors:
Fang Liang Zhang, Jianbing Zhang, Shu Wu
Abstract: The present disclosure relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.
Type:
Grant
Filed:
December 21, 2017
Date of Patent:
November 9, 2021
Assignee:
NOVARTIS AG
Inventors:
Maximilian Aigner, Alexander Wolfgang Koch, Markus Waldhuber
Abstract: The present invention provides glycated Amadori products of the CD59 peptide and fragments thereof to be used as tools and among methods for the diagnosis and prognosis of pre-diabetes and diabetes. Certain aspects of the invention include glycated Amadori products of CD59 and fragments thereof to be used for the generation of antibodies and antibody fragments. Still other aspects of the invention include methodologies for the preparation of glycated Amadori products of CD59, fragments thereof, the inventive antibodies, and antibody fragments.
Type:
Grant
Filed:
June 1, 2018
Date of Patent:
November 2, 2021
Assignee:
President and Fellows of Harvard College
Abstract: The present disclosure relates to antibodies that bind human chitinase-3-like protein 1 (CHI3L1) and uses thereof. In aspects, the antibodies are useful in compositions and methods for detecting and/or treating nonalcoholic steatohepatitis (NAFLD) or nonalcoholic fatty liver disease (NASH) in a subject, as well as subsequent complications of untreated progression in the liver of a subject, such as liver cirrhosis and/or a hepatocellular carcinoma.
Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
Type:
Grant
Filed:
June 26, 2019
Date of Patent:
October 26, 2021
Assignee:
Janssen Pharmaceuticals, Inc.
Inventors:
James Andrew Huntington, Trevor Baglin, Jonathan Langdown
Abstract: The present invention relates to an antibody specifically bound to a coagulation factor VIII or an antigen binding fragment thereof, and a use thereof. More specifically, the present invention relates to: an antibody which is specifically bound to a coagulation factor VIII including specific sequences of heavy chain CDR and light chain CDR, or an antigen binding fragment thereof; a column in which the antibody or the antigen binding fragment thereof is coupled to a column stationary phase as a ligand for isolating or purifying a recombinant coagulation factor VIII; and a method for purifying a recombinant coagulation factor VIII using the same.
Type:
Grant
Filed:
December 14, 2017
Date of Patent:
October 26, 2021
Assignee:
PANGEN BIOTECH INC.
Inventors:
Jaeseung Yoon, Kwanghee Baek, Taeho Byun, Jeong Soo Park, Ji Tai Kim, Hankyu Oh, Jongmin Lee
Abstract: In various embodiments, disclosed herein are assays for measuring thrombin generated (TG) in a blood sample, comprising: incubating the blood sample with TF, FIXa, and CaCl2; and measuring TG in the blood sample. Also disclosed herein are assays for determining a bleeding risk in a subject, comprising obtaining a blood sample from the subject; adding to the blood sample TF and/or FIXa; determining the amount of coagulation factor VIII (FVIII:C) in the blood sample; and determining (a) a mild bleeding risk in the subject if the amount of FVIII:C in the sample is >5 IU/dL, (b) a moderate bleeding risk in the subject if the amount of FVIII:C in the sample is 1-5 IU/dL, and (c) a severe bleeding risk in the subject if the amount of FVIII:C in the subject is <1 IU/dL.
Abstract: The present disclosure provides isolated binding molecules that bind to and blocks PD-L1, vectors comprising a nucleic acid molecules encoding an amino acid sequence of the binding molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring stimulation of immune responses including cancer.
Abstract: This application relates generally to the production of polypeptides having specific antigen-binding properties of Fv domains, for example, insertable variable fragments of antibodies, and modified ?1-?2 domains of NKG2D ligands. This application further relates to modified ?1-?2 domains of NKG2D ligands attached to polypeptides, in some embodiments antibodies or fragments of antibodies. This application further relates to antigen-binding peptides derived from light and heavy chain antibody variable domains, which contain two linker regions and a split variable domain.
Type:
Grant
Filed:
June 24, 2016
Date of Patent:
September 14, 2021
Assignee:
XYPHOS BIOSCIENCES INC.
Inventors:
Kyle Landgraf, Daniel P. Steiger, Steven R. Williams, David W. Martin, Jr., Dana Gebhart, Tarah Baron
Abstract: Provided herein are methods and compositions for disrupting biofilms in vitro and in vivo. Also disclosed are antibodies comprising a specified heavy chain (HC) immunoglobulin variable domain sequence and/or a specified light chain (LC) immunoglobulin variable domain sequence.
Type:
Grant
Filed:
January 28, 2021
Date of Patent:
August 31, 2021
Assignee:
RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL